Koichi Kameda

  • Citations Per Year
Learn More
We examined the discriminant validity of the Inventory to Diagnose Depression, lifetime version (IDDL), that is, a self-report instrument designed to diagnose a lifetime history of major depressive disorder. Remitted patients with major depression (MD), remitted patients with anxiety disorders (ADs) and controls completed the IDDL. The IDDL results were(More)
We examined the discriminant validity of the Inventory to Diagnose Depression (IDD), a self-report instrument designed to diagnose major depressive disorder as defined in DSM-III-R. Forty patients with major depression (MD), 20 patients with anxiety disorders, who had not had a lifetime history of depression (ADs), and 40 control subjects completed the IDD.(More)
Pyrazinamide (PZA), an antituberculosis agent, was first synthesized in 1940 by Hall and Spoerri and a clinical trial was carried out since 1949 by Yeager and others. Its usefulness as a potent antituberculosis drug was first reported by them in 1952. PZA was once believed to be a secondary choice drug for cases with refractory tuberculosis and/or relapsed(More)
The prevailing model for encouraging innovation based on patents and market-oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health(More)